throbber
PCT
`INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`wo 97/47317
`
`WORLD INTELLECTUAL PROPERTY ORGANIZATION
`International Bureau
`
`(51) International Patent Classification 6 :
`A61K 38/31
`
`Al
`
`(11) International Publication Number:
`
`( 43) International Publication Date:
`
`18 December 1997 ( 18.12.97)
`
`(21) International Application Number:
`
`PCTIEP97/03036
`
`(22) International Filing Date:
`
`II June 1997 ( 11.06.97)
`
`(30) Priority Data:
`9612171.0
`9619310.7
`
`II June 1996 (11.06.96)
`GB
`16 September 1996 (16.09.96) GB
`
`(71) Applicant (for all designated States except US); NOV ARTIS
`AG [CHICH]; Schwarzwaldallee 215, CH-4058 Basel (CH).
`
`(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
`BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, Fl, GB, GE,
`GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
`LS, LT. LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
`PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TI,
`UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE,
`LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY,
`KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH,
`DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
`SE), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, ML,
`MR. NE, SN, TD, TG).
`
`(72) Inventor; and
`(75) Inventor/Applicant (for US only): WECKBECKER, Gisbert
`[DEICH]; Loeliring 31, CH-4105 Biel-Benken (CH).
`
`Published
`With international search report.
`
`(74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und
`Markenabteilung, Klybeckstrasse 141, CH-4002 Basel (CH).
`
`(54) Title: COMBINATION OF A SOMATOSTATIN ANALOGUE AND A RAPAMYCIN
`
`(57) Abstract
`
`A combination of a compound of the somatostatin class and a rapamycin macrolide is useful for the prevention or treatment of cell
`hyperproliferation.
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 001
`
`

`
`Codes used to identify States party to the Per on the front pages of pamphlets publishing international applications under the Per.
`
`FOR THE PURPOSES OF INFORMATION ONLY
`
`AL
`AM
`AT
`AU
`AZ
`BA
`DB
`BE
`BF
`BG
`BJ
`DR
`BY
`CA
`CF
`CG
`CH
`Cl
`CM
`CN
`cu
`cz
`DE
`OK
`EE
`
`Albania
`Annenia
`Austria
`Australia
`Arerbaijan
`Bosnia and Herzegovina
`Barbados
`Belgium
`Burkina Faso
`Bulgaria
`Benin
`Brazil
`Belarus
`Canada
`Central African Republic
`Congo
`Switzerland
`Cllte d'Jvoire
`Cameroon
`China
`Cuba
`Czech Republic
`Gennany
`Denmark
`Estonia
`
`ES
`Fl
`FR
`GA
`GB
`GE
`GH
`GN
`GR
`HU
`IE
`IL
`IS
`IT
`JP
`KE
`KG
`KP
`
`KR
`KZ
`LC
`u
`LK
`LR
`
`Spain
`Finland
`France
`Gabon
`United Kingdom
`Georgia
`Ghana
`Guinea
`Greece
`Hungary
`Ireland
`Israel
`Iceland
`Italy
`Japan
`Kenya
`Kyrgyzstan
`Democratic People's
`Republic of Korea
`Republic of Korea
`Kazak51an
`Saint Lucia
`Liechtenstein
`Sri Lanka
`Liberia
`
`LS
`LT
`LU
`LV
`MC
`MD
`MG
`MK
`
`ML
`MN
`MR
`MW
`MX
`NE
`NL
`NO
`NZ
`PL
`PT
`RO
`RU
`SD
`SE
`SG
`
`Lesotho
`Lithuania
`Luxembourg
`Lalvia
`Monaco
`Republic of Moldova
`Madagascar
`The former Yugoslav
`Republic of Macedonia
`Mali
`Mongolia
`Mauritania
`Malawi
`Mexico
`Niger
`Netherlands
`Norway
`New Zealand
`Poland
`Portugal
`Romania
`Russian Federation
`Sudan
`Sweden
`Singapore
`
`Sl
`SK
`SN
`sz
`TD
`TG
`TJ
`TM
`TR
`TT
`UA
`UG
`us
`uz
`VN
`YU
`zw
`
`Slovenia
`Slovakia
`Senegal
`Swaziland
`Chad
`Togo
`Tajikistan
`Turkmenistan
`Turkey
`Trinidad and Tobago
`Ukraine
`Uganda
`United States of America
`Uzbekistan
`VietNam
`Yugoslavia
`Zimbabwe
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 002
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`COMBINATION OF A SOMATOSTATIN ANALOGUE AND A RAPAMYCIN
`
`The present invention relates to a pharmaceutical combination and its use in the
`
`treatment of disorders associated with excess benign and malignant cell proliferation, e.g.
`
`tumors or intimal cell proliferation.
`
`There is a continuing need for the development of drugs having increased
`
`effectiveness in inhibiting or slowing down undesired cell proliferation, particularly in the
`
`cancer field and in vasculopathies.
`
`Accordingly, there is provided a pharmaceutical combination comprising a
`
`compound of the somatostatin class, and a rapamycin macrolide.
`
`The somatostatin class is a known class of small peptides comprising the naturally
`
`occurring somatostatin-14 and analogues having somatostatin related activity, e.g. as
`
`disclosed by A.S. Dutta in Small Peptides, Vol.19, Elsevier (1993). By "somatostatin
`
`analogue" as used herein is meant any straight-chain or cyclic polypeptide having a
`
`structure based on that of the naturally occurring somatostatin-14 wherein one or more
`
`amino acid units have been omitted and/or replaced by one or more other amino radical(s)
`
`and/or wherein one or more functional groups have been replaced by one or more other
`
`functional groups and/or one or more groups have been replaced by one or several other
`
`isosteric groups. In general, the term covers all modified derivatives of the native
`
`somatostatin-14 which exhibit a somatostatin related activity, e.g. they bind to at least one
`
`somatostatin receptor (hSST-1, hSST-2, hSST-3, hSST-4 or hSST-5), preferably in the
`
`nMolar range, more preferably to at least the hSST-2 receptor in the nMolar range.
`
`Cyclic, bridge cyclic and straight-chain somatostatin analogues or derivatives are
`
`known and have been described together with processes for their production e.g. in US
`
`Patent Specifications 4,310,518 and 4,235,886, in European Patent Specifications EP(cid:173)
`
`A-1295; 23,192; 29,310; 29,579; 30,920; 31,303; 63,308; 70,021; 83,305; 215,171;
`
`203,031; 214,872; 143,307; 298,732; 277,419; 389,180; 395,417; 450,480A2; in Belgian
`
`Patent Specification BE-A-900,089; and in WO 91109056; WO 97/01579; WO 97/14715,
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 003
`
`

`
`W097/47317
`
`PCT/EP97/03036
`
`2
`
`the contents thereof, in particular with respect to the compounds, being incorporated
`
`herein by reference.
`
`Preferred somatostatin analogues are e. g. compounds of formula I
`
`Y2-S-1H 2
`CH -S-Y
`I 2
`A'
`I
`'N-CH-CO-B-C-D-E-NH- H-G
`A/
`
`(I)
`
`wherein
`
`A is C 1_12alkyl, C7_10phenylalkyl or a group of formula RCO-,
`whereby
`
`i)
`
`R is hydrogen, C 1_11alkyl, phenyl or C7_10phenylalkyl, or
`ii) RCO- is
`
`a)
`
`a D-phenylalanine residue optionally ring-substituted by halogen, N02, NH2, OH,
`C1_3alkyl and/or C 1_3alkoxy; or
`
`b)
`
`the residue of a natural or a synthetic a-amino-acid other than defined under a)
`
`above, or of a corresponding D-amino acid, or
`
`c)
`
`a dipeptide residue in which the individual amino acid residues are the same or
`
`different and are selected from those defined under a) and/or b) above,
`
`the a-amino group of amino acid residues a) and b) and the N-terminal amino group of
`
`dipeptide residues c) being optionally mono- or di-C 1•12alkylated or substituted by
`C 1_8alkanoyl;
`
`A'
`
`is hydrogen or CHalky!,
`
`Y 1 and Y 2 represent together a direct bo.nd or each of Y 1 and Y 2 is hydrogen
`
`B
`
`is -Phe- optionally ring-substituted by halogen, N02, NH2, OH, C 1_3alkyl and lor
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 004
`
`

`
`W097147317
`
`PCT/EP97/03036
`
`3
`
`C 1_3alkoxy (including pentafluoroalanine), naphthylalanine or pyridylalanine,
`
`C
`
`is (L)-Trp- or (D)-Trp- optionally a-N-methylated and optionally benzene(cid:173)
`
`ring-substituted by halogen, N02, NH2, OH, C1_3alkyl and/or C1_3alkoxy,
`
`D
`
`is Lys, 4-aminocyclohexylAla or 4-aminocyclohexylGly
`
`E
`
`is Thr, Ser, Val, Tyr, lie, Leu or an aminobutyric or aminoisobutyric acid residue
`
`G
`
`is a group of formula
`
`or
`
`wherein
`
`R7
`R 10
`
`R 11
`R 12
`R 13
`
`is hydrogen or C1_3alkyl,
`is hydrogen or the residue of a physiologically acceptable, physiologically
`
`hydrolysable ester, e.g. fonnyl, c2-12alkylcarbonyl, benzoyl,
`
`is hydrogen. C1_3alkyl, phenyl or C7_10phenyl-alkyl,
`is hydrogen, C1_3alkyl or a group of fonnula -CH(R 13)-X"
`is CH20H, -(CH2kOH, -(CH2kOH, -CH(CH3)0H, isobutyl, butyl, benzyl,
`naphthyl-methyl or indol-3-yl-methyl, and
`
`X 1 is a group of formula
`
`R
`-CO-N/ 14
`
`" R1s
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 005
`
`

`
`wo 97/47317
`
`wherein
`
`4
`
`PCT/EP97 /03036
`
`R7 and R 10 have the meanings given above,
`R14
`is hydrogen or C 1_3alkyl and
`R15
`is hydrogen, C 1_3alkyl, phenyl or C7_10phenylalkyl, and
`R 16
`is hydrogen or hydroxy,
`
`with the proviso that
`
`when R 1" is -CH(R 13)-X 1 then R 11 is hydrogen or methyl,
`
`wherein the residues B, D and E have the L-configuration, and the residues in the 2- and
`
`7-position each independently have the (L)- or (0)- configuration,
`
`in free fonn or in pharmaceutically acceptable salt or complex form.
`
`Individual compounds of formula I suitable in accordance with the present invention are
`
`the following somatostatin analogues:
`
`a. (D )Phe-2ys-Phe-(D )Trp-Lys-Thr-2ys-Thr-ol
`
`also known as octreotide
`
`b. (D)Phe-~ys-Tyr-(D)Trp-Lys-Val-~ys-ThrNH2
`
`c. (D)Phe-Cys-Tyr-(D)Trp-Lys-Vai-Cys-TrpNH2
`also known as vapreotide
`
`d. (D )Trp-Cys-Phe-(D )Trp-Lys-Thr-Cys-ThrNH 2
`
`e. (D)Phe-~ys-Phe-(D)Trp-Lys-Thr-2ys-ThrNH2
`
`f. 3-(2-(Naphthyl)-(D)Ala-~ys-Tyr-(D)Trp-Lys-Val-tys-ThrNH2
`also known as lanreotide
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 006
`
`

`
`W097/47317
`
`PCT!EP97/03036
`
`5
`
`g. (D)Phe-~ys-Tyr-(D)Trp-Lys-Val-tys-~-Nal-NH2
`
`h. 3-(2-naphthy 1 )-Ala-6ys-Tyr-(D)Trp-Lys-Val-tys-~-Nal-NH2
`
`1. (D)Phe-tys-13-Nal-(D)Trp-Lys-Val-tys-Thr-NH2
`
`J. (D)Phe-Cys-Tyr-(D)Trp-Lys-Leu-Cys-Thr-NH2
`
`k. (D)Phe-tys-Tyr-(D)Trp-Lys-tys-Thr-NH2•
`
`A preferred compound of formula I is octreotide.
`
`Compounds of formula I may exist e.g. in free form, salt form or in the form of
`
`complexes thereof. Acid addition salts may be formed with e.g. organic acids, polymeric
`
`acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides
`
`and acetates. Complexes are e.g. formed from compounds of the invention on addition of
`
`inorganic substances, e.g. inorganic salts or hydroxides such as Ca- and Zn-salts, andlor
`
`an addition of polymeric organic substances.
`
`Further somatostatin analogues suitable for use in accordance with the present
`
`invention are:
`
`cyclo [ -Asn-Phe-Phe-DTrp-Lys-Thr-Phe-Gaba-],
`
`cyclo(Asu-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser), and
`
`I
`I
`(D)Nal-Glu-Tyr-(D)Trp-Lys-Val-Lys-Thr-NH2
`
`According to an alternatively preferred embodiment of the invention, the somatostatin
`
`component of the combination is a somatostatin analogue comprising the amino acid
`
`sequence of formula (II)
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 007
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`6
`
`(II)
`
`(a)
`
`(b)
`
`wherein X2 is a radical of formula (a) or (b)
`
`or
`
`-NH-CH-C0-
`1
`CH-O-CH2·R1
`I
`CH 3
`
`-NH-CH-C0-
`1
`CH2
`I
`R2
`
`wherein R 1 is optionally substituted phenyl,
`R2 is -Z1-CH2-R}t -CH2-CO-O-CH2-R 1,
`
`~0-CH-R ~ 21
`
`or
`
`wherein Z 1 is 0 or S,
`
`and
`
`X3
`
`is an a-amino acid having an aromatic residue on the Ca side chain, or an
`
`amino acid unit selected from Dab, Dpr, Dpm, His,(Bzl)HyPro, thienyl(cid:173)
`
`Ala, cyclohexyl-Ala and t.-butyl-Ala,
`
`the residue Lys of said sequence corresponding to the residue Lys9 of the native
`
`somatostatin-14.
`
`Such somatostatin analogues are e.g. disclosed in WO/ 97/01579, the contents
`
`thereof, in particular with respect to the specifically exemplified compounds, being
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 008
`
`

`
`WO 97147317
`
`PCT/EP97103036
`
`7
`
`incorporated herein by reference.
`
`Preferably the sequence of formula II as defined above corresponds to the residues
`
`at positions 8 through 11 of the somatostatin-14. More preferably the somatostatin
`
`analogue as disclosed above comprises a hexapeptide unit, the residues at positions 3
`
`through 6 of said hexapeptide unit comprising the sequence of formula II. More
`
`particularly the hexapeptide unit is cyclic, e.g. having a direct peptide linkage between the
`
`a.-carbonyl group of the residue at position 6 and the a.-amino group of the residue at
`
`position 1.
`
`While Lys, X" and X3 in the sequence of formula II have the L-configuration, Trp
`may have the D- or L-configuration, preferably the D-configuration.
`
`X~ is preferably a residue of formula (a) or (b), R2 being preferably -Z1-CH2-R 1 or
`~0-CH-R ~ 21 .
`
`When X 3 comprises an aromatic residue on the Ca side chain, it may suitably be a
`natural or unnatural a.-amino acid, e.g. Phe, Tyr, Trp, Nal, Pal, benzothienyl-Ala, Tic and
`
`thyronin, preferably Phe or Nal, more preferably Phe. X3 is preferably an a.-amino acid
`bearing an aromatic residue on the Ca side chain.
`
`When R 1 is substituted phenyl, it may suitably be substituted by halogen, methyl,
`ethyl, methoxy or ethoxy e.g. in ortho and/or para. More preferably R 1 is unsubstituted
`phenyl. zl is preferably 0.
`
`Representative somatostatin analogues comprising a residue of formula II are e.g
`
`compounds of formula (III)
`
`cvclo[A - Z:Z - Trp - Lys - X - X ]
`•
`a
`2
`3
`5
`I
`2
`3
`4
`6
`
`(II)
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 009
`
`

`
`WO 97/47317
`
`PCT/EP97/03036
`
`8
`
`wherein
`X2 and X3 are as defined above,
`a divalent residue selected from Pro,
`A 1 is
`
`(ICO(cid:173)
`I
`v -(CH) -N-N
`2 1-6
`.. "a
`
`wherein R3 is NR8R9-C 2_6alkylene, guanidino-C 2•6alkylene or C2_6alkylene-COOH,
`R33 is H, C 14alkyl or has independently one of the significances given for R3_ R3bis
`H or C 14alkyl, Ra is OH or NRsR6, Rb is -(CH2) 1-r or -CH(CH3)-, R4 is H or CH,,
`R4a is optionally ring-substituted benzyl, each of R5 and R6 independently is H,
`
`cl-4alkyl, (1)-amino-CI-4alkylene, (1)-hydroxy-CI-4alkylene or acyl, Rs. is a direct
`
`bond or C 1_6alkylene, each of R8 and R9 independently is H. C 1_4alkyl,
`())-hydroxy-C24alkylene, acyl or CH20H-(CHOH)c·CH2- wherein c is 0, 1, 2, 3 or
`4, or R8 and R9 form together with the nitrogen atom to which they are attached a
`heterocyclic group which may comprise a further heteroatom, and R 17 is optionally
`ring-substituted benzyl, -(CH2) 1•3-0H, CH3-CH(OH)- or
`-(CH2) 1.5-NR5R6 , and
`ZZa is a natural or unnatural a-amino acid unit.
`
`ZZa may have the D- or L-configuration. When ZZ1 is a natural or unnatural a-amino
`acid unit, it may suitably be e.g. Thr, Ser, Ala, Val, lie, Leu, Nle, His, Arg, Lys, Nal, Pal,
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 010
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`9
`
`Tyr, Trp, optionally ring-substituted Phe or N°-benzyl-Gly. When zz. is Phe, the benzene
`ring thereof may be substituted by e.g. NH2, N02, CH3, OCH3 or halogen, preferably in
`para position. When zz. is Phe, the benzene ring thereof is preferably unsubstituted.
`
`When A1 comprises a Pro amino acid residue, any substituent present on the proline
`ring, e.g. R3-NH-CO-O- etc., is preferably in position 4. Such substituted proline residue
`may exist in the cis form, e.g.
`
`-ob-c-
`
`N
`I
`
`II
`o
`
`as well as in the trans form. The present invention covers each geometric isomer
`
`individually as well as mixtures thereof.
`
`When A1 is (NR8R9-C2_6alkylene-NH-CO-O)P{o- where NR8R9 forms a
`
`heterocyclic group, such group may be aromatic or saturated and may comprise one
`
`nitrogen or one nitrogen and a second heteroatorn selected from nitrogen and oxygen.
`
`Preferably the heterocyclic group is e.g. pyridyl or morpholino. C2_6Aikylene in this
`residue is preferably -CH2-CH2-.
`
`Any acyl as R5, R6 , R8 and R9 in A 1 may be e.g. R 18CO- wherein R18 is H, C 1-4alkyl,
`C2-4alkenyl, C3_6cycloalkyl or benzyl, preferably methyl or ethyl. When R4• or R 17 in A1 is
`ring-substituted benzyl, the benzene ring may be substituted as indicated above for zz..
`
`A preferred group of compounds of formula m are such wherein A 1 is free of a
`lateral -NH-C0-0- moiety. A further group of preferred compounds of formula m are
`such wherein A 1 comprises a basic lateral radical, e.g. a R3-NH-CO-O- or R5-N-R5.-
`I
`
`~
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 011
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`10
`
`moiety.
`
`A still further group of preferred compounds of formula III are such wherein the N(cid:173)
`
`terminal amino acid comprises a substituted Pro, particularly 4-substituted Pro, e.g.
`
`compounds of formula III wherein A 1 is 4-substituted Pro.
`
`Preferably A 1 is 4-(R3-NH-CO-O)Pro.
`
`Examples of somatostatin analogues comprising a residue of formula II include e.g.
`
`cyclof 4-(NH 2-C 2H4- NH-C0-0- )Pro-Phe-DTrp-Lys-Ser(Benzy 1)-Phe].
`
`The term "macrolide" as used herein, refers to a macrocyclic lactone, for example a
`
`compound having a 12-membered or larger lactone ring. Of particular interest are the
`
`"lactam macrolides", i.e. macrocyclic compounds having a lactam (amide) bond in the
`
`macrocycle in addition to a lactone (ester) bond, for example rapamycin and its numerous
`
`derivatives and analogues. Rapamycin is an immunosuppressive Jactam macrolide that is
`
`produced by Streptomyces hy~roscopicus, and having the structure depicted in Formula
`
`A:
`
`sc;x;" ..... ~·· lS
`
`_ll
`ll4
`, ~ .
`
`'
`
`7
`N
`
`J
`
`2
`
`t
`J
`!
`
`(A)
`
`0
`II
`1 ~OH
`
`0~ 0
`0 '
`
`11
`
`I • • &
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 012
`
`

`
`W097/47317
`
`PCT/EP97/03036
`
`11
`
`See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S.L.. eta!.,
`J. Am. Chern. Soc. (1991) ill: 7433; US Patent No.3 929 992. One group of rapamycin
`derivatives are 40-0-substituted derivatives of rapamycin having the structure of
`
`Formula IV:
`
`IV
`
`wherein
`
`X 4 is (H,H) or 0;
`Y 3 is (H,OH) or 0;
`R20 and R21 are independently selected from H, alkyl, arylalkyl, hydroxyalkyl,
`dihydroxyalkyl, hydroxyalkoxycarbonylalkyl, hydroxyalkylarylalkyl,
`
`dihydroxyalkylarylalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl,
`
`alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl,
`
`dihydroxyalkylallyl, dioxolanylallyl, dialkyl-dioxolanylalkyl, di(alkoxycarbonyl)(cid:173)
`
`triazolyl-alkyl and hydroxyalkoxy-alkyl; wherein "alk-" or "alkyl" refers to C 1_6alkyl,
`branched or linear, preferably C 1_3alkyl,; "aryl" is phenyl or tolyl; and acyl is a radical
`derived from a carboxylic acid; and
`R22 is methyl or R22 and R 20 together form C2•6alkyl;
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 013
`
`

`
`W097/47317
`
`PCT/EP97/03036
`
`12
`
`provided that R20 and R21 are not both H; and hydroxyalkoxyalkyl is other than
`hydroxyalkoxymethyl.
`
`Such compounds are disclosed in WO 94/09010 the contents of which, in particular
`
`with respect to the specifically exemplified compounds, are incorporated herein by
`
`reference.
`
`A preferred compound is e.g. 40-0-(2-hydroxy)ethyl-rapamycin (referred thereafter as
`
`Compound B).
`
`Further preferred rapamycin derivatives are e.g. those disclosed in WO 96/41807, the
`
`contents thereof, in particular with respect to the specifically exemplified compounds of
`
`formula I disclosed therein, being incorporated herein by reference. Particularly preferred
`
`are 32-deoxo-rapamycin, 16-0-pent-2-ynyl-32-deoxo-rapamycin,
`
`16-0-pent-2-ynyl-32-deoxo-40-0-(2-hydroxyethyl)-rapamycin,
`
`I 6-0-pent-2-yny 1-32-(S)-dihydro-rapamycin and 16-0-pent-2-yny 1-32-(S )-dihydro-40-0-
`
`(2-hydroxyethyl )-rapamycin.
`
`Further rapamycin derivatives are known, e.g. carboxylic acid esters such as disclosed
`
`in WO 92/05179. amide esters such as disclosed in US 5 118 677, carbamates such as
`
`described in US 5 118 678, fluorinated esters such as disclosed in US 5 100 883, acetals,
`
`e.g. in US 5 151 413, silyl ethers, e.g. in US 5 120 842, arylsulfonates and su1famates,
`
`e.g. in US 5 177 203, derivatives wherein the methoxy group at the position 16 is
`
`replaced with alkynyloxy, e.g. in WO 95/16691 and further derivatives such as disclosed
`
`in WO 93111130, WO 94/02136, WO 94/02385 and WO 95/14023, all incorporated
`
`herein by reference.
`
`Rapamycin and above mentioned derivatives have been shown to have potent
`
`immunosuppressant properties. Rapamycin has also been shown to inhibit smooth muscle
`
`cell proliferation and to inhibit cancer growth.
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 014
`
`

`
`W097/47317
`
`PCT/EP97/03036
`
`13
`
`Somatostatin analogues, e.g. octreotide, vapreotide and lanreotide, have been disclosed
`
`i.a. to inhibit growth hormone secretion and to have an inhibiting effect on malignant
`
`tumor growth, e.g. in breast cancer. Octreotide and lanreotide have also been disclosed to
`
`inhibit smooth muscle cell proliferation.
`
`In accordance with the invention, it has now surprisingly been found that a
`
`combination of 2 active ingredients believed to act on basically different mechanisms
`
`such as a somatostatin analogue and rapamycin or a derivative thereof, can be combined
`
`and synergistically inhibit cell hyperproliferation.
`
`In accordance with the particular findings of the present invention, there is provided in
`
`a first aspect:
`
`I. Use of a compound of the somatostatin class, in free form or in pharmaceutically
`
`acceptable salt form, for manufacturing a pharmaceutical composition for use in
`
`synergistically effective amounts in the prevention or treatment of cell
`
`hyperproliferation in combination with a rapamycin macrolide, e.g. for the manufacture
`
`of a kit as disclosed hereinafter.
`
`2. Use of a compound of the somatostatin class, in free form or in pharmaceutically
`
`acceptable salt form, in combination in synergistically effective amounts with a
`
`rapamycin macrolide for the prevention or treatment of cell hyperproliferation.
`
`3. A method for preventing or treating cell hyperproliferation in a subject in need of such
`
`treatment which comprises administering to such subject a synergistically effective
`
`amount of a compound of the somatostatin class in free form or in pharmaceutically
`
`acceptable salt form, and a rapamycin macrolide.
`
`4. A kit or package for the treatment or prevention of cell hyperproliferation, said kit or
`
`package including a pharmaceutical composition comprising a compound of the
`
`somatostatin class in free form or in pharmaceutically acceptable salt form, and a
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 015
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`14
`
`pharmaceutical composition comprising a rapamycin macrolide. The kit or package
`
`may also contain instructions to use the pharmaceutical compositions in accordance
`
`with the present invention.
`
`According to the invention, the combination of a compound of the somatostatin class
`
`and a rapamycin macrolide is indicated for the prevention or treatment of malignant
`
`tumor growth, e.g. breast, lung, GEP tumors, pituitary adenomas. lymphomas, etc., for the
`
`prevention or treatment of proliferative vascular diseases, e.g. biologically or
`
`mechanically induced vascular injury causing intimal thickening, e.g. restenosis,
`
`atherosclerosis, vascular occlusion, injury following percutaneous transluminal coronary
`
`angioplasty, vascular surgery or transplantation surgery, transplant vasculopathies, for
`
`example chronic rejection of various tissues and organs such as heart, kidney, pancreas,
`
`lung, liver, bowel, trachea and combined heart-lung.
`
`The combination is particularly indicated for preventing intimal smooth muscle cell
`
`hyperplasia, restenosis and vascular occlusion in a mammal.
`
`Utility of the combination in the treatment of disorders and diseases as hereinbefore
`
`specified, may be demonstrated for example in accordance with the method hereinafter
`
`described.
`
`A. In vitro Assay
`
`AR42J cell cultures are propagated in DMEM supplemented with 10% fetal calf
`
`serum (FCS) at 5 % C02• Cells are grown in the absence of antibiotics or antifungal
`agents. Subconfluent AR42J cells growing in DMEM and supplemented with 10% FCS
`are trypsinized, diluted in DMEM + 2.5 % FCS and seeded in uncoated 96-well plates
`
`(5'000 to 10'000 cells per well in 180 J.ll). After a 48-hr incubation period (Day 0), the
`
`number of cells in a separate control plate is determined both by counting cells in a
`
`Coulter counter and by the sulforhoda~ine B (SRB) staining assay. The cells are then
`
`exposed either to the somatostatin analogue alone, e.g. octreotide, or to rapamycin or a
`
`derivative thereof alone or to a combination of the somatostatin analogue and rapamycin
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 016
`
`

`
`WO 97/47317
`
`PCTIEP97/03036
`
`15
`
`or its derivative up to 5 days at various concentrations. Total drug exposure lasts for up
`
`to 5 days following the first addition and SRB analysis as described above is performed
`
`e.g. on day 2 and day 5. Growth is determined as difference in absorbance (00) between
`
`day 0 and day x values (= delta OD). Calculations are made based on the fractional
`
`product method of Webb (Valeriote and Lin, 1975; Cory and Carter, 1986; Berenbaum,
`
`J. Theor. Bioi. 114: 413-431, 1985) and the method by Chou and Talalay
`
`(Adv. Enz. Regul. 22: 27-55, 1984). If the measured cell growth (%of control)
`
`is < to the calculated cell growth, this shows evidence for a synergistic effect. Under
`
`these conditions a combination of a somatostatin analogue at a concentration of from 10· 10
`to 1 o-6 M with a rapamycin macrolide thereof at a concentration of from 1 to 1000 nM
`significantly inhibits the growth of the tumor cells.
`
`In this assay, the following results are obtained with octreotide alone, Compound B
`
`alone and a combination of octreotide and Compound B. The synergy according to the
`
`Webb Method is confirmed by using the Chou-Talalay Method.
`
`Cell Growth (% of CONTROL)
`
`Cell Growth
`(~00)
`(%)
`
`664 ::t 9
`
`397 :!: 16
`
`420:!: 12
`
`103 ± 5
`
`Observed
`(%)
`
`Calculated
`(Webb Method)
`(%)
`
`100
`
`59.8
`
`63.3
`
`15.6
`
`37.9
`
`Concentration
`(nM)
`
`Control
`
`Octreotide
`
`Compound B
`
`Octreotide
`+
`Compound B
`
`1.2
`
`12.0
`
`1.2
`+
`12.0
`
`B. In Vivo Assay
`
`The AR42J (AR4-2J) rat pancreatic tumor cell line is derived from an azaserine(cid:173)
`
`induced exocrine pancreatic tumor (Jessop and Hay, 1980). It was obtained from ATCC.
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 017
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`16
`
`Cultures are propagated in DMEM supplemented with 10% fetal calf serum (FCS) at 59'c
`
`CO~. Cells are grown in the absence of antibiotics or antifungal agents. Female nude mice
`
`(nu/nu Balbc-A from lffa Credo, Lyon, France) weighing 19-22 g, are kept in groups of 5
`animals in macrolon cages (type m, 16 x 22 x 11 em). The cages are placed in ventilated
`cabinets (Iff a Credo) that are maintained at 24 ± I o C. The animals have free access to
`
`drinking water and a pathogen-free rodent diet (Diet A, Kliba, Basel, Switzerland). To
`
`initiate tumors from cultured cells, AR42J cells are trypsinized and lOx I 06 tumor cells (in
`
`0.2 ml) are injected subcutaneously (s.c.) into both flanks of nude mice. When tumors
`
`have reached a volume of 0.03 cm3
`
`, animals are randomized into control and treatment
`
`groups. Control animals receive placebo. Animals are treated as indicated below for 3
`
`weeks with single agents or the drug combination. The somatostatin analogue is given as
`
`a single injection of a slow release form at 30 mglkg s.c .. The size of the tumors is
`
`determined with a caliper. To calculate the tumor volume in ml the equation "volume
`
`(ellipsoid) = length x depth x height x 0.52" was used.
`
`Results
`
`After 4 weeks the following tumor size were determined.
`
`(Please note that values in the control group correspond to 3 week values, since animals
`
`were killed afterwards for tumors became excessively large.)
`
`Treatment
`
`Control
`
`Volume
`
`mm 3
`
`4020
`
`A) Compound B, 5 mglkg p.o.
`
`3685
`
`B) Rapamycin, 5 mglkg p.o.
`
`2748
`
`C) Octreotide pamoate (biodegradable,
`
`sustained release formulation),
`
`30 mg/kg, single inj.
`
`2205
`
`SE
`
`579
`
`263
`
`325
`
`339
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 018
`
`

`
`wo 97/47317
`
`PCT/EP97/03036
`
`17
`
`130
`
`106
`
`75
`
`44
`
`Compound B + octreotide (C)
`
`Rapamycin + octreotide (C)
`
`C. Clinical trial
`
`Patients are included who have breast cancer as evidenced by histological biopsy
`
`(glandular analysis - EOA). They present a metastatic illness and/or loco-regional
`
`localisation which is measurable and evaluable. If desired, patients may be included who
`
`are resistant to other treatment to conventional therapy such as surgery, radiotherapy.
`
`other chemotherapy and/or hormone therapy.
`
`The patients present at least one target, on X-ray analysis, which is measurable or
`
`evaluable such as a primitive metastatic tumour which is cutaneous or sub-cutaneous. It
`
`may be gangliar or visceral. Preferably the patients have lesions which have progressed
`
`within the month preceding the trial and have an estimated survival time of at least 3
`
`months.
`
`The rapamycin macrolide, e.g rapamycin or compound B is administered orally. The
`
`treatment is for at least 3 months or until complete remission. The response may be
`
`followed by conventional methodology, e.g. according to IUCC response criteria, e.g.
`
`progression. stabilization, partial or complete remission.
`
`The somatostatin analogue, e.g. octreotide, is administered parenterally, e.g.
`
`subcutaneous, particularly in a continuous subcutaneous way by means of a portable
`
`syringe pump (infusion pump).
`
`According to the invention, the somatostatin analogue and the rapamycin macrolide
`
`are preferably administered in the form of a pharmaceutical composition. Rapamycin and
`
`its derivatives, e.g. Compound B, may be administered by any conventional route, in
`
`particular enterally, e.g. orally, e.g. in the form of tablets, capsules, drink solutions,
`
`emulsions or microemulsion preconcentrates, nasally, pulmonary (by inhalation),
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 019
`
`

`
`wo 97/47317
`
`PCT!EP97/03036
`
`18
`
`parenterally, e.g. in the form of injectable solutions or suspensions. or topically.
`
`Rapamycin and its derivatives are preferably administered per
`
`os and the somatostatin analogue is preferably administered parenterally, e.g by infusion.
`
`The somatostatin analogue may also be administered in a slow release form, e.g. as
`
`disclosed in UK Patent Specification 2,265,311B. The administration of each component
`
`of the combination may take place either separately, simultaneously or sequentially, e.g.
`
`rapamycin or Compound B may be administered at first followed later, e.g. 8 to 24 hours
`
`later, by the somatostatin analogue.
`
`The amount of each component administered is determined taking into account various
`
`factors such as the etiology and severity of the disease, and the patient's condition.
`
`Rapamycin or its derivatives may conveniently be administered at doses which are in the
`
`range used in immunosuppressive applications such as prevention and treatment of
`
`graft vs. host disease, transplant rejection or autoimmune diseases e.g. at a daily dosage
`
`from about 0.5 to 500 ID6 as a single dose or in divided doses. Such doses may also be
`
`given intermittently, for example, every other day or every third day. The somatostatin
`
`analogue may be administered, e.g. subcutaneously, in a dosage range of about 100 ~g to
`
`10 mg per day as a single dose or in divided doses. Thus octreotide may be administered
`
`at a dose of from 0.2 mg to 10 mg twice or three times daily. When administered as a
`
`slow release form, such formulation may comprise the somatostatin peptide in a
`
`concentration from 2.0 to I 0% by weight. The release period of such a formulation may
`
`be from 1 week to about 2 months. The combination of the somatostatin analogue with
`
`rapamycin or its derivative allows to maximize the antiproliferative effect.
`
`The invention contemplates that the active ingredients discussed herein may be utilized
`
`in combination with pharmaceutically acceptable diluents and carriers.
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 020
`
`

`
`wo 97147317
`
`PCTIEP97/03036
`
`19
`
`Formulation Examples:
`
`A. Somatostatin Formulations:
`
`1. Ampoules
`
`Octreotide
`
`Mannitol
`
`0.5 mg
`
`45.0 mg
`
`Lactic acid (88%)
`
`3.4 mg
`
`Sodium hydrogeno-
`
`carbonate
`
`to pH 4.2
`
`Water (inject.grade)
`
`to 1 ml
`
`Carbon dioxide
`
`q.s.
`
`2. Biodegradable sustained release formulation:
`
`Octreotide Acetate
`
`4.65%
`
`(by weight)
`
`Poly(DL-lactide-co-glycolide)
`
`78.35%
`
`Sterile Mannitol
`
`17%
`
`Vehicle: Carboxymethylcellulose 0.5 %
`
`(by weight)
`
`Mannitol
`
`0.6%
`
`Water for injection
`
`98.9%
`
`B. Rapamycin (or derivative thereoO formulation: e.~. capsules
`
`Ethanol
`
`1 ,2-propylene glycol
`
`Refined oil
`
`Cremophor RH40
`
`Rapamycin or Compound B
`
`Total
`
`20.0 mg
`
`81.0mg
`
`121.5mg
`
`202.5mg
`
`20.0mg
`
`. 500 mg
`
`Par Pharm., Inc.
`Exhibit 1053
`Page 021
`
`

`
`WO 97/47317
`
`PCT/EP97/03036
`
`20
`
`CLAIMS
`
`1.
`
`Use of a compound of the somatostatin class, in free form or in pharmaceutically
`
`acceptable salt form, for manufacturing a pharmaceutical composition for use in
`
`synergistically effective amounts in the prevention or treatment of cell
`
`hyperproliferation in combination with a rapamycin macrolide.
`
`2.
`
`Use of a compound of the somatostatin class, in free form or in pharmaceutically
`
`acceptable salt form, in combination in synergistically

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket